{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:19Z","timestamp":1784566099229,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032665","name":"Innoviva Specialty Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11982-4","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:17:57Z","timestamp":1767025077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Sean R. Van","family":"Helden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlan J. Kunz","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Lena","family":"Kang-Birken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena L. V.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholson B.","family":"Perkins III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin","family":"Agee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina","family":"DeKerlegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"Tart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Pullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie Rae","family":"Schrack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese","family":"Cosimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelbye R.","family":"Herbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Judd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Al","family":"Musawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"1","key":"11982_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"DM Sievert","year":"2013","unstructured":"Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National healthcare safety network at the centers for disease control and Prevention, 2009\u20132010. Infect Control Hosp Epidemiol. 2013;34(1):1\u201314.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"11982_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE. The rise of the enterococcus: beyond Vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266\u201378.","journal-title":"Nat Rev Microbiol"},{"key":"11982_CR3","doi-asserted-by":"crossref","unstructured":"Montravers P, Dupont H, Leone M, Constantin JM, Mertes PM, et al. Societe francaise d\u2019anesthesie et de r,. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34(2):117\u2009\u2013\u200930.","DOI":"10.1016\/j.accpm.2015.03.005"},{"issue":"16","key":"11982_CR4","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1016\/j.jmb.2019.05.030","volume":"431","author":"PHN Kao","year":"2019","unstructured":"Kao PHN, Kline KA. Dr. Jekyll and Mr. Hide: how Enterococcus faecalis subverts the host immune response to cause infection. J Mol Biol. 2019;431(16):2932\u201345.","journal-title":"J Mol Biol"},{"issue":"5\u20136","key":"11982_CR5","doi-asserted-by":"publisher","first-page":"106665","DOI":"10.1016\/j.ijantimicag.2022.106665","volume":"60","author":"EA Shephard","year":"2022","unstructured":"Shephard EA, Mondy K, Reveles KR, Jaso T, Rose DT. A comparison of outcomes with and without infectious diseases consultation for enterococcal bacteraemia in a multicenter healthcare system. Int J Antimicrob Agents. 2022;60(5\u20136):106665.","journal-title":"Int J Antimicrob Agents"},{"key":"11982_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jgar.2022.05.003","volume":"29","author":"L Bussini","year":"2022","unstructured":"Bussini L, Del Rosselli E, Pasquini Z, Scolz K, Amedeo A, Beci G, et al. Risk factors for persistent enterococcal bacteraemia: a multicentre retrospective study. J Glob Antimicrob Resist. 2022;29:386\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"11982_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41579-024-01058-6","volume":"22","author":"Y Wei","year":"2024","unstructured":"Wei Y, Palacios Araya D, Palmer KL. Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics. Nat Rev Microbiol. 2024;22(11):705\u201321.","journal-title":"Nat Rev Microbiol"},{"key":"11982_CR8","unstructured":"CDC. Antimicrobial resistance threats in the united States, 2021\u20132022. Centers for Disease Control and Prevention July; 2024."},{"issue":"4","key":"11982_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1086\/502196","volume":"24","author":"X Song","year":"2003","unstructured":"Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol. 2003;24(4):251\u20136.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"11982_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/430909","volume":"41","author":"CA DiazGranados","year":"2005","unstructured":"DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41(3):327\u201333.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11982_CR11","doi-asserted-by":"publisher","first-page":"ofab659","DOI":"10.1093\/ofid\/ofab659","volume":"9","author":"RA Lee","year":"2022","unstructured":"Lee RA, Goldman J, Haidar G, Lewis J, Arif S, Hand J, et al. Daptomycin-Resistant Enterococcus bacteremia is associated with prior daptomycin use and increased mortality after liver transplantation. Open Forum Infect Dis. 2022;9(3):ofab659.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"11982_CR12","doi-asserted-by":"publisher","first-page":"e0454522","DOI":"10.1128\/spectrum.04545-22","volume":"11","author":"H Faury","year":"2023","unstructured":"Faury H, Le Guen R, Demontant V, Rodriguez C, Souhail B, Galy A, et al. Ampicillin-susceptible Enterococcus faecium infections: clinical features, causal clades, and contribution of MALDI-TOF to early detection. Microbiol Spectr. 2023;11(5):e0454522.","journal-title":"Microbiol Spectr"},{"key":"11982_CR13","unstructured":"Zyvox. (linezolid) [package insert]. New York, NY: Pfizer Inc. 2013."},{"issue":"5","key":"11982_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1086\/338403","volume":"34","author":"K Attassi","year":"2002","unstructured":"Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695\u20138.","journal-title":"Clin Infect Dis"},{"key":"11982_CR15","unstructured":"Wheeler M, Jensen L, Dalfopristin, Injection Q. June. American society of health-system pharmacists drug shortages database. 26 September 2022. Accessed 9 2025. https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=823#:~:text=Pfizer%20discontinued%20Synercid%20in%20early,other%20suppliers%20of%20the%20product"},{"issue":"1","key":"11982_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","volume":"24","author":"WM Texidor","year":"2024","unstructured":"Texidor WM, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, et al. Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect Dis. 2024;24(1):127.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"11982_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jmii.2025.03.001","volume":"58","author":"C Hidalgo-Tenorio","year":"2025","unstructured":"Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Aparicio-Minguijon E, Alarcon A, Plata A, Martinez Marcos FJ, et al. Real-world evidence of Dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp. J Microbiol Immunol Infect. 2025;58(4):429\u201336.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"11982_CR18","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.21873\/invivo.13795","volume":"38","author":"S Jalali","year":"2024","unstructured":"Jalali S, Bhatt H, Thakkar K, Julka R, Pasikhova Y, Verma N. Management of recurrent Vancomycin-resistant Enterococcus faecium bacteremia with oritavancin: A case report. Vivo. 2024;38(6):3106\u201311.","journal-title":"Vivo"},{"issue":"1","key":"11982_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/1120009X.2023.2247205","volume":"36","author":"C Di Cecco","year":"2024","unstructured":"Di Cecco C, Monticelli J, Di Bella S, Di Maso V, Luzzati R. Vancomycin-resistant Enterococcus bloodstream infection successfully managed with Oritavancin and fosfomycin as sequential treatment. J Chemother. 2024;36(1):31\u20134.","journal-title":"J Chemother"},{"issue":"2","key":"11982_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","volume":"6","author":"CL Stewart","year":"2017","unstructured":"Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-World experience with Oritavancin therapy in invasive Gram-Positive infections. Infect Dis Ther. 2017;6(2):277\u201389.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"11982_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","volume":"53","author":"GM Leanza","year":"2025","unstructured":"Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, et al. A systematic review of Dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025;53(1):15\u201323.","journal-title":"Infection"},{"issue":"4","key":"11982_CR22","doi-asserted-by":"publisher","first-page":"106945","DOI":"10.1016\/j.ijantimicag.2023.106945","volume":"62","author":"J Courjon","year":"2023","unstructured":"Courjon J, Senneville E, Illes HG, Pavese P, Boutoille D, Daoud FC, et al. Effectiveness and safety of Dalbavancin in france: a prospective, multicentre cohort study. Int J Antimicrob Agents. 2023;62(4):106945.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"11982_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/526772","volume":"46","author":"M Billeter","year":"2008","unstructured":"Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46(4):577\u201383.","journal-title":"Clin Infect Dis"},{"key":"11982_CR24","doi-asserted-by":"crossref","unstructured":"Carvalhaes CG, Mendes RE, Shortridge D, Castanheira M. 734. Trend analysis of Oritavancin and comparator agents activity against Enterococcus causing infections in US medical centers between 2017\u20132019 and 2022. Open Forum Infect Dis. 2023;10(Suppl 2).","DOI":"10.1093\/ofid\/ofad500.795"},{"key":"11982_CR25","doi-asserted-by":"crossref","unstructured":"Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN, Longitudinal. (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016;71(12):3453-8.","DOI":"10.1093\/jac\/dkw319"},{"key":"11982_CR26","unstructured":"Drug Approval Package. XERAVA (eravacycline) [press release]. 2 ed. Online: U.S. Food & Drug Administration. Oct 2018."},{"key":"11982_CR27","unstructured":"Xerava (eravacycline) Online: European medicines agency. 2018 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xerava#authorisation-details]"},{"issue":"3","key":"11982_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","volume":"40","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Evaluation of eravacycline: A novel fluorocycline. Pharmacotherapy. 2020;40(3):221\u201338.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"11982_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of Eravacycline vs ertapenem in complicated Intra-abdominal infections in the investigating Gram-Negative infections treated with Eravacycline (IGNITE 1) trial: A randomized clinical trial. JAMA Surg. 2017;152(3):224\u201332.","journal-title":"JAMA Surg"},{"issue":"6","key":"11982_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","volume":"69","author":"JS Solomkin","year":"2019","unstructured":"Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, et al. IGNITE4: results of a phase 3, Randomized, Multicenter, prospective trial of Eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69(6):921\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"11982_CR31","doi-asserted-by":"publisher","first-page":"e0235123","DOI":"10.1128\/spectrum.02351-23","volume":"12","author":"AJ Kunz Coyne","year":"2024","unstructured":"Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. Regions from 2018 to 2022. Microbiol Spectr. 2024;12(1):e0235123.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"11982_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"key":"11982_CR33","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"11982_CR34","volume-title":"IBM SPSS statistics for Macintosh, version 30.0.0.0 Armonk","author":"Released","year":"2024","unstructured":"IBM, Released. IBM SPSS statistics for Macintosh, version 30.0.0.0 Armonk. NY: IBM Corp; 2024."},{"issue":"10","key":"11982_CR35","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"issue":"5","key":"11982_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"11982_CR37","unstructured":"CLSI M100-ED 34:2024 performance standards for antimicrobial susceptibility testing, 34th Edition. 34 ed: Clinical and Laboratory Standards Institute. 2024."},{"key":"11982_CR38","first-page":"Doc07","volume":"4","author":"M Kresken","year":"2016","unstructured":"Kresken M, Korber-Irrgang B, Petrik C, Seifert H, Rodloff A, Becker K. Temporal trends of the in vitro activity of Tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006\u20132014: results of the Tigecycline evaluation and surveillance trial (TEST). GMS Infect Dis. 2016;4:Doc07.","journal-title":"GMS Infect Dis"},{"issue":"4","key":"11982_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/1440-1681.13066","volume":"46","author":"W Zamoner","year":"2019","unstructured":"Zamoner W, Prado IRS, Balbi AL, Ponce D. Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice. Clin Exp Pharmacol Physiol. 2019;46(4):292\u2013301.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"11982_CR40","doi-asserted-by":"publisher","first-page":"ofab568","DOI":"10.1093\/ofid\/ofab568","volume":"8","author":"M Samura","year":"2021","unstructured":"Samura M, Hirose N, Kurata T, Takada K, Nagumo F, Koshioka S, et al. Identification of risk factors for Daptomycin-Associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability. Open Forum Infect Dis. 2021;8(12):ofab568.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"11982_CR41","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.7150\/ijms.38605","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Baus C, Wilson JP, Frei CR. Rhabdomyolysis associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system (FAERS). Int J Med Sci. 2019;16(11):1504\u20139.","journal-title":"Int J Med Sci"},{"issue":"4","key":"11982_CR42","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"BH Dvorchik","year":"2003","unstructured":"Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"11982_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000535190","volume":"69","author":"A Di Lorenzo","year":"2024","unstructured":"Di Lorenzo A, Rindi LV, Campogiani L, Imeneo A, Alessio G, Pace PG, et al. Daptomycin-Induced eosinophilic pneumonia: A case report and systematic review. Chemotherapy. 2024;69(2):85\u201399.","journal-title":"Chemotherapy"},{"issue":"8","key":"11982_CR44","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkac164","volume":"77","author":"YC Chuang","year":"2022","unstructured":"Chuang YC, Lin HY, Yang JL, Lin CY, Huang SH, Wang JT, et al. Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin. J Antimicrob Chemother. 2022;77(8):2278\u201387.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"11982_CR45","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/cid\/ciad386","volume":"77","author":"R Garreau","year":"2023","unstructured":"Garreau R, Pham TT, Bourguignon L, Millet A, Parant F, Bussy D, et al. Daptomycin exposure as a risk factor for Daptomycin-Induced eosinophilic pneumonia and muscular toxicity. Clin Infect Dis. 2023;77(10):1372\u201380.","journal-title":"Clin Infect Dis"},{"key":"11982_CR46","doi-asserted-by":"crossref","unstructured":"Santimaleeworagun W, Changpradub D, Thunyaharn S, Hemapanpairoa J. Optimizing the dosing regimens of daptomycin based on the susceptible dose-dependent breakpoint against vancomycin-resistant enterococci infection. Antibiot (Basel). 2019;8(4).","DOI":"10.3390\/antibiotics8040245"},{"issue":"2","key":"11982_CR47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01289-13","volume":"58","author":"EP Balli","year":"2014","unstructured":"Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother. 2014;58(2):734\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"11982_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Wang JT, Lin HY, Chang SC. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis. 2014;14:687.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"11982_CR49","doi-asserted-by":"publisher","first-page":"105059","DOI":"10.1016\/j.cmicom.2025.105059","volume":"2","author":"JC Pearson","year":"2025","unstructured":"Pearson JC, Gillett E, Gadri ND, Dionne B. Tetracyclines, the old and the new: A narrative review. CMI Commun. 2025;2(1):105059.","journal-title":"CMI Commun"},{"key":"11982_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/IDR.S294282","volume":"14","author":"C Zhou","year":"2021","unstructured":"Zhou C, Jin L, Wang Q, Wang X, Chen F, Gao Y, et al. Bloodstream infections caused by Carbapenem-Resistant enterobacterales: risk factors for Mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist. 2021;14:731\u201342.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"11982_CR51","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","volume":"37","author":"L Zha","year":"2020","unstructured":"Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose Tigecycline for the treatment of severe infections: A systematic review and Meta-Analysis. Adv Ther. 2020;37(3):1049\u201364.","journal-title":"Adv Ther"},{"issue":"3","key":"11982_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3947\/ic.2020.52.3.345","volume":"52","author":"W Santimaleeworagun","year":"2020","unstructured":"Santimaleeworagun W, Hemapanpairoa J, Changpradub D, Thunyaharn S. Optimizing the dosing regimens of Tigecycline against Vancomycin-Resistant enterococci in the treatment of Intra-abdominal and skin and soft tissue infections. Infect Chemother. 2020;52(3):345\u201351.","journal-title":"Infect Chemother"},{"issue":"1","key":"11982_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","volume":"44","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"11982_CR54","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/phar.2185","volume":"38","author":"KE Barber","year":"2018","unstructured":"Barber KE, Bell AM, Wingler MJB, Wagner JL, Stover KR. Omadacycline enters the ring: A new antimicrobial contender. Pharmacotherapy. 2018;38(12):1194\u2013204.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"11982_CR55","doi-asserted-by":"publisher","first-page":"e0298018","DOI":"10.1371\/journal.pone.0298018","volume":"19","author":"N Akazawa","year":"2024","unstructured":"Akazawa N, Itoh N, Mano-Usui F, Tatsuoka H, Terada N, Kurai H. To treat or not to treat: assessing the role of anti-enterococcal therapy for intra-abdominal infections in patients with cancer. PLoS ONE. 2024;19(2):e0298018.","journal-title":"PLoS ONE"},{"issue":"8","key":"11982_CR56","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/sur.2017.121","volume":"18","author":"JM Sanders","year":"2017","unstructured":"Sanders JM, Tessier JM, Sawyer R, Dellinger EP, Miller PR, Namias N, et al. Does isolation of Enterococcus affect outcomes in Intra-Abdominal infections? Surg Infect (Larchmt). 2017;18(8):879\u201385.","journal-title":"Surg Infect (Larchmt)"},{"issue":"9","key":"11982_CR57","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/jac\/dkaf225","volume":"80","author":"TH Ou","year":"2025","unstructured":"Ou TH, Yang JL, Lin CY, Huang SH, Chuang YC, Wang JT, et al. Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection. J Antimicrob Chemother. 2025;80(9):2408\u201316.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11982-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:01:57Z","timestamp":1767027717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11982"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11982-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted using de-identified data and did not involve direct patient contact. As such, informed consent was waived by the Institutional Review Board. This study was reviewed and approved by the institutional review boards at Wayne State University (052019MP2X, protocol number 1905002252) and at each participating site and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"MJR has received grant support\/consulted or has participated on a speaker bureau for AbbVie, Innoviva, Melinta, Merck, and Shionogi. BMJ has consulted for or participated on a speaker bureau for Innovivia, AbbVie, Paratek, and Ferring. KCM has received grant support\/consulted for Melintia, Merck, and Shionogi. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1754"}}